Boston Millennia Partners provides private equity financing to high growth companies in the healthcare and life sciences industry. Our team brings over one hundred years of combined private equity experience to the investment process. Our broad experience, combined with expertise in finance; operations; engineering; life sciences research and development; partnering with pharmaceutical companies; business development; executive recruiting; and law provides significant value to the companies in which we invest. Since the early 1980’s, members of our team have managed seven venture capital partnerships with very successful results for our investors and our entrepreneurs. The growth and success of our portfolio companies have, in turn, allowed us to grow and expand our capital base to over $700 million under management.
Our portfolio company's device "represents the first meaningful improvement for the management of heart failure in nearly a decade."
William Abraham, M.D.
CHAMPION Principal Investigator
Study results indicate that the CHAMPION implantable hemodynamic monitoring system significantly reduces the leading cause of hospitalizations in the U.S.
Histogenics Begins Phase III Study of NeoCart® Implant for Knee Repair
Boston Millennia Partners portfolio company, Histogenics, announced today that it has launched the Phase III study of cartilage repair to evaluate the NeoCart® autologous tissue implant in repairing knee cartilage injury. The study is the largest in the U.S. comprised of 245 patients.
ABC Video - Help for Your Heart
Our portfolio company CardioMEMS' device represents the first meaningful improvement for the management of heart failure in nearly a decade.
Parexel Corporation Earnings Announcement
PAREXEL International Corporation (NASDAQ:PRXL), an important strategic partner of BMP, has achieved a superb quarter of results for its investors with a book to bill of 1.6 times.
Click Here to receive news updates 
